Antidepressants Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Automotive Antidepressants Market
The Antidepressants Market size was valued at USD 11.67 billion in 2023, and the market is now projected to grow to 18.29 USD billion by 2032, exhibiting a CAGR of 2.9% during the forecast period of 2023-2030.
This has affected the overall supply and demand chains of the particular market. As a result of the government's lockdown and other steps to stop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related to this domain. Due to an increase in product sales linked to the COVID-19 emergency, the COVID-19 epidemic has had a favorable effect on the growth of the antidepressant market. Major worldwide OEMs have halted manufacturing as the number of COVID-19 victims rises daily. These factors affected the Antidepressants Market Growth.
This is the major factor attributing the growth of this particular market. This factor is majorly involved in taking the revenue numbers above the skies and soaring greater heights and also the sales and demands have been proliferation and increased its value to greater extent. A lot of growth has been observed in the recent times because of this particular factor that contributed and also acted as a catalyst to the overall development of the product market. Market participants are placing an increasing amount of attention on research and development in order to launch novel and creative therapies for mental health conditions. The development of novel candidates and pharmacological molecules for the treatment of mental disorders and neurological problems, including depression, has the potential to be very profitable due to new discoveries and research evaluating combination treatments with both new and current therapeutic molecules. This has ultimately outraged the sales and demand for this particular market growth and prosperity. These particular growth driving factors have been recorded to attribute the Antidepressants Market share.
A latest trend has been witnessed to proliferate the market growth. This particular trend has been recorded to be the most profiting trends that have been upgraded to augment the overall market growth. A lot of specifications have been made to this particular product which has benefited the market growth. One of the main causes of disability in the world today is major depressive disorder, or MDD. This specific trend has influenced the market growth so much so that the revenue and share numbers of this particular product is touching the skies and soaring over. Patients and healthcare professionals now have an unmet need for cutting-edge medications to treat mental health issues.
Comprehensive Analysis of Antidepressants Market
The segmentation of this particular market has been divided and then further subdivided into various categories. The worldwide market is divided into two segments based on the type of system: virtual and physical acoustics testing. The market is divided into segments according to the application, such as body, drivetrain, powertrain, and interior. The market is divided into passenger automobiles and commercial vehicles according to the kind of vehicle.
This specific region held the biggest revenue share. In North America, the market was worth billions of dollars. This particular region has experienced immense proliferation in the market shares and has attributed to the global market revenue. The need for novel medications in the United States is being fueled by a number of factors, including the high incidence of depression in the general population, increased rates of mental illness diagnosis and treatment, and appropriate reimbursement regulations. This particular region has augmented a lot in the past few years in this particular product market.
Global markets are fiercely competitive and highly fragmented. Due to their creative packaging solutions, a few group of large market companies hold a fair amount of market share. Some of the major Companies includes H. Lundbeck A/S (Europe), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Janssen Pharmaceuticals ( Belgium), and Pfizer Inc. (U.S.).
In June 2021, This particular company has attributed the market growth in terms of revenue and shares system. Together with a deal for the innovative antidepressant candidate NC-2800, which is undergoing clinical trials, Nippon Chemiphar Co. Ltd. and Sumitomo Dainippon Pharma Co., Ltd. jointly announced a research and development partnership. This particular development and investment the global market has been recorded to be a boon for the market growth.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Billion)
Segmentation Drug Class; Disorder; Distribution Channel; and Region
By Drug Class
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antidepressants
Tricyclic Antidepressants (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Others
By Disorder
Major Depressive Disorder
Obsessive Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America
By Drug Class
By Disorder
By Distribution Channel
By Country
The USA (By Disorder)
Canada (By Disorder)
Europe
By Drug Class
By Disorder
By Distribution Channel
By Country
The UK (By Disorder)
Germany (By Disorder)
France (By Disorder)
Italy (By Disorder)
Spain (By Disorder)
Scandinavia (By Disorder)
Rest of Europe (By Disorder)
Asia Pacific
By Drug Class
By Disorder
By Distribution Channel
By Country
Japan (By Disorder)
China (By Disorder)
India (By Disorder)
Australia (By Disorder)
Southeast Asia (By Disorder)
Rest of Asia Pacific (By Disorder)
Latin America
By Drug Class
By Disorder
By Distribution Channel
By Country
Brazil (By Disorder)
Mexico (By Disorder)
Rest of Latin America (By Disorder)
The Middle East & Africa
By Drug Class
By Disorder
By Distribution Channel
By Country
GCC (By Disorder)
South Africa (By Disorder)
Rest of the MEA (By Disorder)
- 1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Anxiety & Depression –Key Regions/Country
- 4.2. New Product Launch
- 4.3. Pipeline Analysis
- 4.4. Impact of COVID-19 on the Antidepressants Market
- 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
- 5. Global Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 5.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 5.2.3. Atypical Antidepressants
- 5.2.4. Tricyclic Antidepressants (TCAs)
- 5.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 5.2.6. Others
- 5.3. Market Analysis, Insights and Forecast – By Disorder
- 5.3.1. Major Depressive Disorder
- 5.3.2. Obsessive Compulsive Disorder
- 5.3.3. Generalized Anxiety Disorder
- 5.3.4. Panic Disorder
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast – By Geography
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Drug Class
- 6.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 6.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 6.2.3. Atypical Antidepressants
- 6.2.4. Tricyclic Antidepressants (TCAs)
- 6.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 6.2.6. Others
- 6.3. Market Analysis, Insights and Forecast – By Disorder
- 6.3.1. Major Depressive Disorder
- 6.3.2. Obsessive Compulsive Disorder
- 6.3.3. Generalized Anxiety Disorder
- 6.3.4. Panic Disorder
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.1.1. By Disorder
- 6.5.1.1.1. Major Depressive Disorder
- 6.5.1.1.2. Obsessive Compulsive Disorder
- 6.5.1.1.3. Generalized Anxiety Disorder
- 6.5.1.1.4. Panic Disorder
- 6.5.1.1.5. Others
- 6.5.2. Canada
- 6.5.2.1. By Disorder
- 6.5.2.1.1. Major Depressive Disorder
- 6.5.2.1.2. Obsessive Compulsive Disorder
- 6.5.2.1.3. Generalized Anxiety Disorder
- 6.5.2.1.4. Panic Disorder
- 6.5.2.1.5. Others
- 7. Europe Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Drug Class
- 7.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 7.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 7.2.3. Atypical Antidepressants
- 7.2.4. Tricyclic Antidepressants (TCAs)
- 7.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 7.2.6. Others
- 7.3. Market Analysis, Insights and Forecast – By Disorder
- 7.3.1. Major Depressive Disorder
- 7.3.2. Obsessive Compulsive Disorder
- 7.3.3. Generalized Anxiety Disorder
- 7.3.4. Panic Disorder
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.5.1. U.K.
- 7.5.1.1. By Disorder
- 7.5.1.1.1. Major Depressive Disorder
- 7.5.1.1.2. Obsessive Compulsive Disorder
- 7.5.1.1.3. Generalized Anxiety Disorder
- 7.5.1.1.4. Panic Disorder
- 7.5.1.1.5. Others
- 7.5.2. Germany
- 7.5.2.1. By Disorder
- 7.5.2.1.1. Major Depressive Disorder
- 7.5.2.1.2. Obsessive Compulsive Disorder
- 7.5.2.1.3. Generalized Anxiety Disorder
- 7.5.2.1.4. Panic Disorder
- 7.5.2.1.5. Others
- 7.5.3. France
- 7.5.3.1. By Disorder
- 7.5.3.1.1. Major Depressive Disorder
- 7.5.3.1.2. Obsessive Compulsive Disorder
- 7.5.3.1.3. Generalized Anxiety Disorder
- 7.5.3.1.4. Panic Disorder
- 7.5.3.1.5. Others
- 7.5.4. Spain
- 7.5.4.1. By Disorder
- 7.5.4.1.1. Major Depressive Disorder
- 7.5.4.1.2. Obsessive Compulsive Disorder
- 7.5.4.1.3. Generalized Anxiety Disorder
- 7.5.4.1.4. Panic Disorder
- 7.5.4.1.5. Others
- 7.5.5. Italy
- 7.5.5.1. By Disorder
- 7.5.5.1.1. Major Depressive Disorder
- 7.5.5.1.2. Obsessive Compulsive Disorder
- 7.5.5.1.3. Generalized Anxiety Disorder
- 7.5.5.1.4. Panic Disorder
- 7.5.5.1.5. Others
- 7.5.6. Scandinavia
- 7.5.6.1. By Disorder
- 7.5.6.1.1. Major Depressive Disorder
- 7.5.6.1.2. Obsessive Compulsive Disorder
- 7.5.6.1.3. Generalized Anxiety Disorder
- 7.5.6.1.4. Panic Disorder
- 7.5.6.1.5. Others
- 7.5.7. Rest of Europe
- 7.5.7.1. By Disorder
- 7.5.7.1.1. Major Depressive Disorder
- 7.5.7.1.2. Obsessive Compulsive Disorder
- 7.5.7.1.3. Generalized Anxiety Disorder
- 7.5.7.1.4. Panic Disorder
- 7.5.7.1.5. Others
- 8. Asia Pacific Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Drug Class
- 8.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 8.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 8.2.3. Atypical Antidepressants
- 8.2.4. Tricyclic Antidepressants (TCAs)
- 8.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 8.2.6. Others
- 8.3. Market Analysis, Insights and Forecast – By Disorder
- 8.3.1. Major Depressive Disorder
- 8.3.2. Obsessive Compulsive Disorder
- 8.3.3. Generalized Anxiety Disorder
- 8.3.4. Panic Disorder
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.5.1. Japan
- 8.5.1.1. By Disorder
- 8.5.1.1.1. Major Depressive Disorder
- 8.5.1.1.2. Obsessive Compulsive Disorder
- 8.5.1.1.3. Generalized Anxiety Disorder
- 8.5.1.1.4. Panic Disorder
- 8.5.1.1.5. Others
- 8.5.2. China
- 8.5.2.1. By Disorder
- 8.5.2.1.1. Major Depressive Disorder
- 8.5.2.1.2. Obsessive Compulsive Disorder
- 8.5.2.1.3. Generalized Anxiety Disorder
- 8.5.2.1.4. Panic Disorder
- 8.5.2.1.5. Others
- 8.5.3. India
- 8.5.3.1. By Disorder
- 8.5.3.1.1. Major Depressive Disorder
- 8.5.3.1.2. Obsessive Compulsive Disorder
- 8.5.3.1.3. Generalized Anxiety Disorder
- 8.5.3.1.4. Panic Disorder
- 8.5.3.1.5. Others
- 8.5.4. Australia
- 8.5.4.1. By Disorder
- 8.5.4.1.1. Major Depressive Disorder
- 8.5.4.1.2. Obsessive Compulsive Disorder
- 8.5.4.1.3. Generalized Anxiety Disorder
- 8.5.4.1.4. Panic Disorder
- 8.5.4.1.5. Others
- 8.5.5. Southeast Asia
- 8.5.5.1. By Disorder
- 8.5.5.1.1. Major Depressive Disorder
- 8.5.5.1.2. Obsessive Compulsive Disorder
- 8.5.5.1.3. Generalized Anxiety Disorder
- 8.5.5.1.4. Panic Disorder
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Disorder
- 8.5.6.1.1. Major Depressive Disorder
- 8.5.6.1.2. Obsessive Compulsive Disorder
- 8.5.6.1.3. Generalized Anxiety Disorder
- 8.5.6.1.4. Panic Disorder
- 8.5.6.1.5. Others
- 9. Latin America Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Drug Class
- 9.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 9.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 9.2.3. Atypical Antidepressants
- 9.2.4. Tricyclic Antidepressants (TCAs)
- 9.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 9.2.6. Others
- 9.3. Market Analysis, Insights and Forecast – By Disorder
- 9.3.1. Major Depressive Disorder
- 9.3.2. Obsessive Compulsive Disorder
- 9.3.3. Generalized Anxiety Disorder
- 9.3.4. Panic Disorder
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.5.1. Brazil
- 9.5.1.1. By Disorder
- 9.5.1.1.1. Major Depressive Disorder
- 9.5.1.1.2. Obsessive Compulsive Disorder
- 9.5.1.1.3. Generalized Anxiety Disorder
- 9.5.1.1.4. Panic Disorder
- 9.5.1.1.5. Others
- 9.5.2. Mexico
- 9.5.2.1. By Disorder
- 9.5.2.1.1. Major Depressive Disorder
- 9.5.2.1.2. Obsessive Compulsive Disorder
- 9.5.2.1.3. Generalized Anxiety Disorder
- 9.5.2.1.4. Panic Disorder
- 9.5.2.1.5. Others
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Disorder
- 9.5.3.1.1. Major Depressive Disorder
- 9.5.3.1.2. Obsessive Compulsive Disorder
- 9.5.3.1.3. Generalized Anxiety Disorder
- 9.5.3.1.4. Panic Disorder
- 9.5.3.1.5. Others
- 10. Middle East & Africa Antidepressants Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Drug Class
- 10.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
- 10.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
- 10.2.3. Atypical Antidepressants
- 10.2.4. Tricyclic Antidepressants (TCAs)
- 10.2.5. Monoamine Oxidase Inhibitors (MAOIs)
- 10.2.6. Others
- 10.3. Market Analysis, Insights and Forecast – By Disorder
- 10.3.1. Major Depressive Disorder
- 10.3.2. Obsessive Compulsive Disorder
- 10.3.3. Generalized Anxiety Disorder
- 10.3.4. Panic Disorder
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.5.1. GCC
- 10.5.1.1. By Disorder
- 10.5.1.1.1. Major Depressive Disorder
- 10.5.1.1.2. Obsessive Compulsive Disorder
- 10.5.1.1.3. Generalized Anxiety Disorder
- 10.5.1.1.4. Panic Disorder
- 10.5.1.1.5. Others
- 10.5.2. South Africa
- 10.5.2.1. By Disorder
- 10.5.2.1.1. Major Depressive Disorder
- 10.5.2.1.2. Obsessive Compulsive Disorder
- 10.5.2.1.3. Generalized Anxiety Disorder
- 10.5.2.1.4. Panic Disorder
- 10.5.2.1.5. Others
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Disorder
- 10.5.3.1.1. Major Depressive Disorder
- 10.5.3.1.2. Obsessive Compulsive Disorder
- 10.5.3.1.3. Generalized Anxiety Disorder
- 10.5.3.1.4. Panic Disorder
- 10.5.3.1.5. Others
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Company Profiles (Overview, Drug Class, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.3.1. H. Lundbeck A/S
- 11.3.1.1. Overview,
- 11.3.1.2. Drug Class,
- 11.3.1.3. SWOT Analysis,
- 11.3.1.4. Recent Developments,
- 11.3.1.5. Strategies,
- 11.3.1.6. Financials (Based on Availability)
- 11.3.2. GlaxoSmithKline plc
- 11.3.2.1. Overview,
- 11.3.2.2. Drug Class,
- 11.3.2.3. SWOT Analysis,
- 11.3.2.4. Recent Developments,
- 11.3.2.5. Strategies,
- 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Eli Lilly and Company
- 11.3.3.1. Overview,
- 11.3.3.2. Drug Class,
- 11.3.3.3. SWOT Analysis,
- 11.3.3.4. Recent Developments,
- 11.3.3.5. Strategies,
- 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Janssen Pharmaceuticals
- 11.3.4.1. Overview,
- 11.3.4.2. Drug Class,
- 11.3.4.3. SWOT Analysis,
- 11.3.4.4. Recent Developments,
- 11.3.4.5. Strategies,
- 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Pfizer Inc.
- 11.3.5.1. Overview,
- 11.3.5.2. Drug Class,
- 11.3.5.3. SWOT Analysis,
- 11.3.5.4. Recent Developments,
- 11.3.5.5. Strategies,
- 11.3.5.6. Financials (Based on Availability)
- 11.3.6. Merck & Co. Inc.
- 11.3.6.1. Overview,
- 11.3.6.2. Drug Class,
- 11.3.6.3. SWOT Analysis,
- 11.3.6.4. Recent Developments,
- 11.3.6.5. Strategies,
- 11.3.6.6. Financials (Based on Availability)
- 11.3.7. AztraZeneca
- 11.3.7.1. Overview,
- 11.3.7.2. Drug Class,
- 11.3.7.3. SWOT Analysis,
- 11.3.7.4. Recent Developments,
- 11.3.7.5. Strategies,
- 11.3.7.6. Financials (Based on Availability)
- 11.3.8. Bristol-Myers Squibb
- 11.3.8.1. Overview,
- 11.3.8.2. Drug Class,
- 11.3.8.3. SWOT Analysis,
- 11.3.8.4. Recent Developments,
- 11.3.8.5. Strategies,
- 11.3.8.6. Financials (Based on Availability)
- 11.3.9. Teva Pharmaceutical Industries Ltd.
- 11.3.9.1. Overview,
- 11.3.9.2. Drug Class,
- 11.3.9.3. SWOT Analysis,
- 11.3.9.4. Recent Developments,
- 11.3.9.5. Strategies,
- 11.3.9.6. Financials (Based on Availability)
- 11.3.10. Other Prominent Players
- 11.3.10.1. Overview,
- 11.3.10.2. Drug Class,
- 11.3.10.3. SWOT Analysis,
- 11.3.10.4. Recent Developments,
- 11.3.10.5. Strategies,
- 11.3.10.6. Financials (Based on Availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook